Research map: Practical management of BRAF inhibitors in glioma: toxicity and resistance

Back to the article

Papers in this map

  1. Mutations of the BRAF gene in human cancer · Helen Ruth Davies · 2002 · 10794 citations · Cited by this paper
  2. Postradiation platinum–etoposide in adult medulloblastomas: retrospective analysis of hematological toxicity · 2024 · Related
  3. Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma · Keith T. Flaherty · 2012 · 2180 citations · Cited by this paper
  4. Very long-term survival of an older glioblastoma patient after treatment with cilengitide: a case report · 2023 · Related
  5. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF -Mutated Melanoma · Georgina Venetia Long · 2017 · 1504 citations · Cited by this paper
  6. Prolonged remission with ibrutinib maintenance therapy following radiation in a patient with relapsed primary CNS lymphoma · 2024 · Related
  7. Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma · Alan G. Mackay · 2017 · 1307 citations · Cited by this paper
  8. Adult pilocytic astrocytoma in the molecular era: a comprehensive review · 2021 · Related
  9. Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma · Junfei Zhao · 2019 · 976 citations · Cited by this paper
  10. Intracranial hypotension in a breast cancer patient treated with epidural blood patches · 2023 · Related
  11. Clonal evolution of glioblastoma under therapy · Jiguang Wang · 2016 · 811 citations · Cited by this paper
  12. Neurofilament light chain in serum of cancer patients with acute neurological complications · 2024 · Related
  13. Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial · Michael A. Davies · 2017 · 785 citations · Cited by this paper
  14. Daily functioning in glioma survivors: associations with cognitive function, psychological factors and quality of life · 2022 · Related
  15. Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors · Erick J. Morris · 2013 · 697 citations · Cited by this paper
  16. An expanded safety/feasibility study of the EMulate Therapeutics Voyager™ System in patients with recurrent glioblastoma · 2023 · Related
  17. Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers · Conan Grant Kinsey · 2019 · 659 citations · Cited by this paper
  18. A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma · 2022 · Related
  19. V600E BRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathway · Christine A. Pratilas · 2009 · 626 citations · Cited by this paper
  20. Meningioma: not always a benign tumor. A review of advances in the treatment of meningiomas · 2021 · Related
  21. Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS · Zhan Yao · 2017 · 580 citations · Cited by this paper
  22. BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition · Zhan Yao · 2015 · 564 citations · Cited by this paper
  23. Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas · Scott T. Ryall · 2020 · 492 citations · Cited by this paper
  24. The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition · Xiaofeng Jiang · 2012 · 485 citations · Cited by this paper
  25. Autophagy Sustains Mitochondrial Glutamine Metabolism and Growth of Braf V600E–Driven Lung Tumors · Anne M. Strohecker · 2013 · 437 citations · Cited by this paper
  26. RAF inhibitors that evade paradoxical MAPK pathway activation · Chao Zhang · 2015 · 395 citations · Cited by this paper
  27. Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial · Patrick Y Wen · 2021 · 370 citations · Cited by this paper
  28. BRAF Inhibition in BRAF V600 -Mutant Gliomas: Results From the VE-BASKET Study · Thomas Joseph Kaley · 2018 · 356 citations · Cited by this paper
  29. Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma · Sarah Joanne Welsh · 2015 · 344 citations · Cited by this paper
  30. Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma · Paolo A. Ascierto · 2019 · 330 citations · Cited by this paper
  31. Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations · Éric Bouffet · 2023 · 300 citations · Cited by this paper
  32. Autophagy Inhibition Improves Chemosensitivity in BRAFV600E Brain Tumors · Jean M. Mulcahy Levy · 2014 · 262 citations · Cited by this paper
  33. Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management · Lucie Heinzerling · 2019 · 235 citations · Cited by this paper
  34. ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors · Georgia Hatzivassiliou · 2012 · 214 citations · Cited by this paper
  35. RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling · Zhan Yao · 2018 · 201 citations · Cited by this paper
  36. KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma · Pier Francesco Ferrucci · 2020 · 193 citations · Cited by this paper
  37. The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial · Lindsay Baker Kilburn · 2023 · 191 citations · Cited by this paper
  38. Autophagy inhibition overcomes multiple mechanisms of resistance to BRAF inhibition in brain tumors · Jean M. Mulcahy Levy · 2017 · 179 citations · Cited by this paper
  39. Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG) · Christopher James Anker · 2016 · 162 citations · Cited by this paper

Source: OpenAlex (CC0)